Endocrinology Medical News about Antiatherogenic Profile

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A Favorable Metabolic and Antiatherogenic Profile in Carriers of CYP21A2 Gene Mutations Supports the Theory of a Survival Advantage in This Population
Hormone Research, 10/27/09

Livadas S et al. – The findings that carriers of CYP21A2 gene mutations have a more favorable internal milieu with regard to the metabolic syndrome and atherogenesis support the theory that heterozygous CYP21A2 mutations provide a survival advantage. The mechanisms involved may be related to the insulin secretion–action pathway, hypothalamic–pituitary–adrenal axis responsiveness or other still unrecognized factors.

<< Previous
Association of Changes in Self-Efficacy, Voluntary Physical...

Next >>
Congenital Adrenal Hyperplasia due to 11-Hydroxylase Deficiency -...